argenx NV ADR (ARGX)vsCompugen (CGEN)
ARGX
argenx NV ADR
$872.58
-1.13%
HEALTHCARE · Cap: $54.24B
CGEN
Compugen
$2.34
+4.24%
HEALTHCARE · Cap: $221.33M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7216% more annual revenue ($5.32B vs $72.66M). CGEN leads profitability with a 48.0% profit margin vs 32.3%. CGEN appears more attractively valued with a PEG of 1.29. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CGEN
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$872.58
$1555.11 discount
Intrinsic value data unavailable for CGEN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Keeps 48 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 184.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 4.7%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : CGEN
The strongest argument for CGEN centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 48.0% and operating margin at -414.4%. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CGEN
The primary concerns for CGEN are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CGEN is a declining play — different risk/reward profiles.
CGEN carries more volatility with a beta of 2.77 — expect wider price swings.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 50/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compugen
HEALTHCARE · BIOTECHNOLOGY · USA
Compugen Ltd., a clinical-stage therapeutic discovery and development company, is engaged in the research, development, and commercialization of therapeutic candidates and products in Israel, the United States, and Europe. The company is headquartered in Holon, Israel.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?